VCIM
ESPR

Velan Capital Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Velan Capital Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.71M Buy
1,720,000
+510,000
+42% +$1.61M 2.95% 10
2025
Q4 		$4.48M Buy
+1,210,000
New +$3.91M 2.6% 12

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Velan Capital Investment Management's ESPR Position: Q1 2026 in Review

Velan Capital Investment Management increased its Esperion Therapeutics (ESPR) stake by 42% in Q1 2026, buying an estimated $1.61M and bringing the position to 1,720,000 shares worth $4.71M. The position accounts for 2.95% of the portfolio, ranked #10.

Velan Capital Investment Management first reported a position in ESPR in Q4 2025 and has held it in 2 quarters since. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Velan Capital Investment Management held 1,720,000 shares of Esperion Therapeutics worth $4.71M as of Q1 2026.
  • Velan Capital Investment Management bought 510,000 Esperion Therapeutics shares in Q1 2026, an estimated $1.61M.
  • Esperion Therapeutics made up 2.95% of Velan Capital Investment Management's portfolio in Q1 2026, its #10 holding.
  • Velan Capital Investment Management first reported a position in Esperion Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.